StonvexLoading…
StonvexStonvexStonvexCore line items from DOC's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $603.99M | $568.48M | $527.42M | $494.94M |
Operating Income | $284.29M | $273.17M | $314.94M | $9.44M |
Net Income | $71.35M | $243.14M | $306.01M | $500.45M |
EPS (Diluted) | $0.10 | $0.36 | $0.56 | $0.92 |
Total Assets | $20.34B | $19.94B | $15.70B | $15.77B |
Total Liabilities | $12.03B | $10.88B | $8.77B | $8.48B |
Cash & Equivalents | $467.46M | $119.82M | $117.64M | $72.03M |
Free Cash Flow OCF − CapEx | $357.01M | $333.73M | $181.68M | $-61.73M |
Shares Outstanding | 695.04M | 699.49M | 547.16M | 546.64M |